navan
/
Daily-Dose
mirror of https://github.com/navanchauhan/Daily-Dose.git
1
0
Fork 0
Code Issues Projects Releases Wiki Activity

added data for 11th Nov 20

This commit is contained in:
Navan Chauhan 2020-11-11 07:51:41 +05:30
parent 2cc49dd68e
commit c6ba6a4ceb
3 changed files with 412 additions and 4 deletions
Show Stats Download Patch File Download Diff File Expand all files Collapse all files

242
archive-covid-19/11 November, 2020.html Normal file
View File

@ -0,0 +1,242 @@
<!DOCTYPE html>
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
<meta charset="utf-8"/>
<meta content="pandoc" name="generator"/>
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
<title>11 November, 2020</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
.display.math{display: block; text-align: center; margin: 0.5rem auto;}
</style>
<!--[if lt IE 9]>
<script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
<![endif]-->
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-preprints">From Preprints</a></li>
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
<li><a href="#from-pubmed">From PubMed</a></li>
<li><a href="#from-patent-search">From Patent Search</a></li>
</ul>
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
<ul>
<li><strong>Susceptibility of well-differentiated airway epithelial cell cultures from domestic and wildlife animals to SARS-CoV-2</strong> -
<div>
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally, and the number of cases continues to rise all over the world. Besides humans, the zoonotic origin, as well as intermediate and potential spillback host reservoirs of SARS-CoV-2 are unknown. To circumvent ethical and experimental constraints, and more importantly, to reduce and refine animal experimentation, we employed our airway epithelial cell (AEC) culture repository composed of various domesticated and wildlife animal species to assess their susceptibility to SARS-CoV-2. In this study, we inoculated well-differentiated animal AEC cultures of monkey, cat, ferret, dog, rabbit, pig, cattle, goat, llama, camel, and two neotropical bat species with SARS-CoV-2. We observed that SARS-CoV-2 only replicated efficiently in monkey and cat AEC culture models. Whole-genome sequencing of progeny virus revealed no obvious signs of nucleotide transitions required for SARS-CoV-2 to productively infect monkey and cat epithelial airway cells. Our findings, together with the previously reported human-to-animal spillover events warrants close surveillance to understand the potential role of cats, monkeys, and closely related species as spillback reservoirs for SARS-CoV-2.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2020.11.10.374587v1" target="_blank">Susceptibility of well-differentiated airway epithelial cell cultures from domestic and wildlife animals to SARS-CoV-2</a>
</div></li>
<li><strong>In Vitro Efficacy of “Essential Iodine Drops” Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)</strong> -
<div>
Background: Aerosolization of respiratory droplets is considered the main route of coronavirus disease 2019 (COVID-19). Therefore, reducing the viral load of Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) shed via respiratory droplets is potentially an ideal strategy to prevent the spread of the pandemic. The in vitro virucidal activity of intranasal Povidone-Iodine (PVP-I) has been demonstrated recently to reduce SARS-CoV-2 viral titres. This study evaluated the virucidal activity of the aqueous solution of Iodine-V (a clathrate complex formed by elemental iodine and fulvic acid) as in Essential Iodine Drops (EID) with 200 microgram elemental iodine/ml content against SARS-CoV-2 to ascertain whether it is a better alternative to PVP-I. Methods: SARS-CoV-2 (USAWA1/2020 strain) virus stock was prepared by infecting Vero 76 cells (ATCC CRL-1587) until cytopathic effect (CPE). The virucidal activity of EID against SARS-CoV-2 was tested in three dilutions (1:1; 2:1 and 3:1) in triplicates by incubating at room temperature (22 +/- 2 Celsius) for either 60 or 90 seconds. The surviving viruses from each sample were quantified by a standard end-point dilution assay. Results: EID (200 microgram iodine/ml) after exposure for 60 and 90 seconds was compared to controls. In both cases, the viral titre was reduced by 99% (LRV 2.0). The 1:1 dilution of EID with virus reduced SARS-CoV-2 virus from 31,623 cell culture infectious dose 50% (CCCID50) to 316 CCID50 within 90 seconds. Conclusion: Substantial reductions in LRV by Iodine-V in EID confirmed the activity of EID against SARS-CoV-2 in vitro, demonstrating that Iodine-V in EID is effective at inactivating the virus in vitro and therefore suggesting its potential application intranasally to reduce SARS-CoV-2 transmission from known or suspected COVID-19 patients.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2020.11.07.370726v1" target="_blank">In Vitro Efficacy of “Essential Iodine Drops” Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)</a>
</div></li>
<li><strong>How to detect and reduce potential sources of biases in epidemiologic studies of SARS-CoV-2</strong> -
<div>
In response to the coronavirus disease (COVID-19) pandemic, public health scientists have produced a large and rapidly expanding body of literature that aims to answer critical questions, such as the proportion of the population in a geographic area that has been infected; the transmissibility of the virus and factors associated with high infectiousness or susceptibility to infection; which groups are the most at risk of infection, morbidity and mortality; and the degree to which antibodies confer protection to re-infection. Observational studies are subject to a number of different biases, including confounding, selection bias, and measurement error, that may threaten their validity or influence the interpretation of their results. To assist in the critical evaluation of a vast body of literature and contribute to future study design, we outline and propose solutions to biases that can occur across different categories of observational studies of COVID-19. We consider potential biases that could occur in five categories of studies: (1) cross-sectional seroprevalence, (2) longitudinal seroprotection, (3) risk factor studies to inform interventions, (4) studies to estimate the secondary attack rate, and (5) studies that use secondary attack rates to make inferences about infectiousness and susceptibility.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/46am5/" target="_blank">How to detect and reduce potential sources of biases in epidemiologic studies of SARS-CoV-2</a>
</div></li>
<li><strong>Increasing both specificity and sensitivity of SARS-CoV-2 antibody tests by using an adaptive orthogonal testing approach</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background SARS-CoV-2 antibody tests have undergone a remarkable improvement in performance. However, due to the low seroprevalence in several areas, very high demands are made on their specificity. Furthermore, the low antibody-response in some individuals requires high test sensitivity to avoid underestimating true seroprevalence. Optimization of testing has been reported through lowering manufacturer cut-offs to improve SARS-CoV-2 assay sensitivity or by combining two tests to improve specificity at the cost of sensitivity. However, these strategies have thus far been used in isolation of each other. Methods To increase sensitivity, cut-offs of three commercially available SARS-CoV-2 automated assays (Roche, Abbott, and DiaSorin) were reduced according to published values in a pre-pandemic specificity cohort (n=1117) and a SARS-CoV-2 positive cohort (n=64). All three testing systems were combined in an orthogonal approach with a confirmatory test, which was one of the remaining automated assays or one of two commercial ELISAs directed against the spike protein receptor binding-domain (RBD) or the nucleocapsid antigen (NP). Results The modified orthogonal test strategy resulted in an improved specificity of at least 99.8%, often even 100%, in all 12 tested combinations with no significant decline in sensitivity. In our cohort, regardless of whether the assays were used for screening or confirmation, combining Roche and Abbott delivered the best overall performance (+~10% sensitivity compared to the single tests and 100% specificity). Conclusion Here we propose a novel orthogonal assay strategy that approaches 100% specificity while maintaining or even significantly improving the screening test9s sensitivity.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.05.20226449v2" target="_blank">Increasing both specificity and sensitivity of SARS-CoV-2 antibody tests by using an adaptive orthogonal testing approach</a>
</div></li>
<li><strong>Excess mortality during the COVID-19 pandemic in Aden governorate, Yemen: a geospatial and statistical analysis</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
(ENGLISH) Background The burden of COVID-19 in low-income and conflict-affected countries is still unclear, largely reflecting low testing rates. In parts of Yemen, reports indicated a peak in hospital admissions and burials during May-June 2020. To estimate excess mortality during the epidemic period, we quantified activity across all identifiable cemeteries within Aden governorate in Yemen (population approximately one million) by analysing very high-resolution satellite imagery, and compared estimates to Civil Registry office records from the city. Methods After identifying active cemeteries through remote and ground information, we applied geospatial analysis techniques to manually identify new grave plots and measure changes in burial surface area over a period from July 2016 to September 2020. After imputing missing grave counts using surface area data, we used alternative approaches, including simple interpolation and a generalised additive mixed growth model, to predict both actual and counterfactual (no epidemic) burial rates by cemetery and across the governorate during the most likely period of COVID-19 excess mortality (from 1 April 2020), and thereby compute excess burials. We also analysed death notifications to the Civil Registry office during April-July 2020 and in previous years. Results We collected 78 observations from 11 cemeteries, of which 10 required imputation from burial surface area. Cemeteries ranged in starting size from 0 to 6866 graves. In all but one a peak in daily burial rates was evident from April to July 2020. Interpolation and mixed model methods estimated ≈ 1500 excess burials up to 6 July, and 2120 up to 19 September, corresponding to a peak weekly increase of 230% from the counterfactual. Satellite imagery estimates were generally lower than Civil Registry data, which indicated a peak 1823 deaths in May alone. However, both sources suggested the epidemic had waned by September 2020. Discussion To our knowledge this is the first instance of satellite imagery being used for population mortality estimation. Findings suggest a substantial, under-ascertained impact of COVID-19 in this urban Yemeni governorate, and are broadly in line with previous mathematical modelling predictions, though our method cannot distinguish direct from indirect virus deaths. Satellite imagery burial analysis appears a promising novel approach for monitoring epidemics and other crisis impacts, particularly where ground data are difficult to collect.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.10.27.20216366v2" target="_blank">Excess mortality during the COVID-19 pandemic in Aden governorate, Yemen: a geospatial and statistical analysis</a>
</div></li>
<li><strong>Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Understanding the factors that mediate overdispersion in SARS-CoV-2 transmissibility is crucial towards mitigating the COVID-19 pandemic. Using a systematically developed dataset, we meta-analyze respiratory viral loads (rVLs) of SARS-CoV-2, SARS-CoV-1 and influenza A(H1N1)pdm09 from 15 countries and model infectiousness by shedding viable virus via droplets and aerosols. Our results indicate heterogeneity in rVL as an intrinsic virological factor facilitating greater overdispersion in the COVID-19 pandemic than in the 2009 H1N1 pandemic. For COVID-19, case heterogeneity remains broad throughout the infectious period, including for pediatric and asymptomatic infections. Many cases inherently present minimal transmission risk, whereas highly infectious individuals shed tens to thousands of SARS-CoV-2 virions/min via droplets and aerosols while breathing, talking and singing. Coughing increases the contagiousness, especially in close contact, of symptomatic cases relative to asymptomatic ones. Our findings show how individual case variations influence SARS-CoV-2 transmissibility and present considerations for disease control.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.10.13.20212233v2" target="_blank">Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols</a>
</div></li>
<li><strong>Vaccine optimization for COVID-19, who to vaccinate first?</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
A vaccine, when available, will likely become our best tool to control the cur- rent COVID-19 pandemic. Even in the most optimistic scenarios, vaccine shortages will likely occur. Using an age-stratified mathematical model paired with optimization algorithms, we determined optimal vaccine allocation for four different metrics (deaths, symptomatic infections, and maximum non- ICU and ICU hospitalizations) under many scenarios. We find that a vaccine with effectiveness ≥50% would be enough to substantially mitigate the ongo- ing pandemic provided that a high percentage of the population is optimally vaccinated. When minimizing deaths, we find that for low vaccine effective- ness, irrespective of vaccination coverage, it is optimal to allocate vaccine to high-risk (older) age-groups first. In contrast, for higher vaccine effectiveness, there is a switch to allocate vaccine to high-transmission (younger) age-groups first for high vaccination coverage. While there are other societal and ethical considerations, this work can provide an evidence-based rationale for vaccine prioritization.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.08.14.20175257v2" target="_blank">Vaccine optimization for COVID-19, who to vaccinate first?</a>
</div></li>
<li><strong>The COVID-19 Pandemic and US Presidential Elections</strong> -
<div>
What is the effect of the COVID-19 pandemic on the 2020 U.S. presidential election? Guided by a pre-analysis plan, we estimate the effect of COVID-19 cases and deaths on the change in county-level voting for Donald Trump between 2016 and 2020. To account for potential confounders, we include a large number of COVID-19-related controls as well as demographic and socioeconomic variables. Moreover, we instrument the numbers of cases and deaths with the share of workers employed in meat-processing factories to sharpen our identification strategy. We find that COVID-19 cases negatively affected Trump’s vote share. The estimated effect appears strongest in urban counties, in swing states, and in states that Trump won in 2016. A simple counterfactual analysis suggests that Trump would likely have won re-election if COVID-19 cases had been 5 percent lower. Our paper contributes to the literature of retrospective voting and demonstrates that voters hold leaders accountable for their (mis-)handling of negative shocks.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/preprints/metaarxiv/sxajv/" target="_blank">The COVID-19 Pandemic and US Presidential Elections</a>
</div></li>
<li><strong>Anti-Intellectualism and the Mass Public’s Response to the Covid-19 Pandemic</strong> -
<div>
Anti-intellectualism – the generalized distrust of experts and intellectuals – is an important concept in explaining the public’s engagement with advice from scientists and experts. We ask whether it has shaped the mass public’s response to COVID-19. We provide evidence of a consistent connection between anti-intellectualism and COVID-19 risk perceptions, social distancing, mask usage, misperceptions, and information search behaviour using a representative survey of 27,615 Canadians conducted from March to July 2020. We exploit a panel-component of our design (N=4,910) to mitigate the threat of endogeneity and strongly link anti-intellectualism and within-respondent change in mask usage. Finally, we provide experimental evidence of anti-intellectualism’s importance in information search behaviour with two conjoint studies (N~2,500) that show respondents ’ preferences for COVID-19 news and COVID-19 information from experts dissipate among those with higher levels of anti-intellectual sentiment. Anti-intellectualism poses a fundamental challenge in maintaining and increasing public compliance with expert-guided COVID-19 health directives.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/agm57/" target="_blank">Anti-Intellectualism and the Mass Public’s Response to the Covid-19 Pandemic</a>
</div></li>
<li><strong>Digital interventions to mitigate the negative impact of the COVID-19 pandemic on public mental health: a rapid meta-review</strong> -
<div>
Background: Digital interventions may be used to mitigate psychosocial consequences of the COVID-19 pandemic but evidence-based recommendations are lacking. The aim of this rapid meta-review was to investigate the theoretical base, user perspective, safety, effectiveness, and cost effectiveness of digital interventions in public mental health provision (i.e. mental health promotion, prevention of, and treatment for mental disorder). Methods: A rapid meta-review was conducted. MEDLINE, PsychINFO, and CENTRAL databases were searched on May 11, 2020. Study inclusion criteria were broad and considered systematic reviews that investigated digital tools for health promotion, prevention, or treatment of mental health conditions likely affected by the COVID-19 pandemic. Findings: We identified 813 reviews of which 82 met inclusion criteria. Overall, there is good evidence on the usability, safety, acceptance/satisfaction, and effectiveness of eHealth interventions while evidence on mHealth apps is promising, especially if social components (e.g. blended care) and strategies to promote adherence are incorporated. Although most digital interventions focus on the prevention or treatment of mental disorders, there is some evidence on mental health promotion. However, evidence on long-term clinical effects, process quality, and cost-effectiveness is very limited. Interpretation: Accumulating evidence suggests negative effects of the COVID-19 pandemic on public mental health. There is evidence that digital interventions are particularly suited to mitigating psychosocial consequences at the population level. Decision-makers should develop digital strategies for continued mental health care and the development and implementation of mental health promotion and prevention programs in times of quarantine and social distancing.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://psyarxiv.com/uvc78/" target="_blank">Digital interventions to mitigate the negative impact of the COVID-19 pandemic on public mental health: a rapid meta-review</a>
</div></li>
<li><strong>Asymptomatic Employee Screening for SARS-CoV-2: Implementation of and Reactions to an Employer-Based Testing Program.</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Introduction. Asymptomatic testing for SARS-CoV-2 among healthcare workers or other essential personnel could remove infected carriers from the workforce, decreasing chances for transmission and workplace outbreaks. Results from one-time testing programs have been reported but data regarding longitudinal testing, including information about employees reactions to such programs, is not readily available. Methods. To identify asymptomatic carriers of SARS-CoV-2, we implemented a longitudinal screening program for critical on-site employees within our research institute in early April 2020. We conducted a survey of both on-site employees and those working from home in order to measure their reactions to the testing program. Statistical analysis of the survey was conducted with general linear regression and Pearsons Chi-Square tests. Results. Despite an ongoing high community prevalence rate of COVID-19, to date only two asymptomatic employees tested positive out of 1050 tests run during 7 months of the program. However, 12 symptomatic employees not participating in the program have tested positive. The employee survey was completed by 132/306 (43%) employees, with 93% agreeing that asymptomatic employee screening led to a better and safer working environment and 75% agreeing with on-site public health measures to help contain the virus, but only 58% feeling COVID-19 was a serious threat to their health. Conclusion. Our results suggest that a longitudinal asymptomatic employee screening program for SARS-CoV-2 can be accepted by employees and can be used to maintain the health of the workforce, potentially keeping positivity rates below community levels in the face of the ongoing COVID-19 pandemic.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.06.20227314v1" target="_blank">Asymptomatic Employee Screening for SARS-CoV-2: Implementation of and Reactions to an Employer-Based Testing Program.</a>
</div></li>
<li><strong>Challenges of Deep Learning Methods for COVID-19 Detection Using Public Datasets</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
A large number of studies in the past months have proposed deep learning-based Artificial Intelligence (AI) tools for automated detection of COVID-19 using publicly available datasets of Chest X-rays (CXRs) or CT scans for training and evaluation. Most of these studies report high accuracy when classifying COVID-19 patients from normal or other commonly occurring pneumonia cases. However, these results are often obtained on cross-validation studies without an independent test set coming from a separate dataset and have biases such as the two classes to be predicted come from two completely different datasets. In this work, we investigate potential overfitting and biases in such studies by designing different experimental setups within the available public data constraints and highlight the challenges and limitations of developing deep learning models with such datasets. We propose a deep learning architecture for COVID-19 classification that combines two very popular classification networks, ResNet and Xception, and use it to carry out the experiments to investigate challenges and limitations. The results show that the deep learning models can overestimate their performance due to biases in the experimental design and overfitting to the training dataset. We compare the proposed architecture to state-of-the-art methods utilizing an independent test set for evaluation, where some of the identified bias and overfitting issues are reduced. Although our proposed deep learning architecture gives the best performance with our best possible setup, we highlight the challenges in comparing and interpreting various deep learning algorithms9 results. While the deep learning-based methods using chest imaging data show promise in being helpful for clinical management and triage of COVID-19 patients, our experiments suggest that a larger, more comprehensive database with less bias is necessary for developing tools applicable in real clinical settings.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.07.20227504v1" target="_blank">Challenges of Deep Learning Methods for COVID-19 Detection Using Public Datasets</a>
</div></li>
<li><strong>ConceptWAS: a high-throughput method for early identification of COVID-19 presenting symptoms</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Objective: Identifying symptoms highly specific to COVID-19 would improve the clinical and public health response to infectious outbreaks. Here, we describe a high-throughput approach - Concept-Wide Association Study (ConceptWAS) that systematically scans a disease9s clinical manifestations from clinical notes. We used this method to identify symptoms specific to COVID-19 early in the course of the pandemic. Methods: Using the Vanderbilt University Medical Center (VUMC) EHR, we parsed clinical notes through a natural language processing pipeline to extract clinical concepts. We examined the difference in concepts derived from the notes of COVID-19-positive and COVID-19-negative patients on the PCR testing date. We performed ConceptWAS using the cumulative data every two weeks for early identifying specific COVID-19 symptoms. Results: We processed 87,753 notes 19,692 patients (1,483 COVID-19-positive) subjected to COVID-19 PCR testing between March 8, 2020, and May 27, 2020. We found 68 clinical concepts significantly associated with COVID-19. We identified symptoms associated with increasing risk of COVID-19, including “absent sense of smell” (odds ratio [OR] = 4.97, 95% confidence interval [CI] = 3.21-7.50), “fever” (OR = 1.43, 95% CI = 1.28-1.59), “with cough fever” (OR = 2.29, 95% CI = 1.75-2.96), and “ageusia” (OR = 5.18, 95% CI = 3.02-8.58). Using ConceptWAS, we were able to detect loss sense of smell or taste three weeks prior to their inclusion as symptoms of the disease by the Centers for Disease Control and Prevention (CDC). Conclusion: ConceptWAS is a high-throughput approach for exploring specific symptoms of a disease like COVID-19, with a promise for enabling EHR-powered early disease manifestations identification.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.06.20227165v1" target="_blank">ConceptWAS: a high-throughput method for early identification of COVID-19 presenting symptoms</a>
</div></li>
<li><strong>COVID-19 detection on IBM quantum computer with classical-quantum transfer learning</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Diagnose the infected patient as soon as possible in the coronavirus 2019 (COVID-19) outbreak which is declared as a pandemic by the world health organization (WHO) is extremely important. Experts recommend CT imaging as a diagnostic tool because of the weak points of the nucleic acid amplification test (NAAT). In this study, the detection of COVID-19 from CT images, which give the most accurate response in a short time, was investigated in the classical computer and firstly in quantum computers. Using the quantum transfer learning method, we experimentally perform COVID-19 detection in different quantum real processors (IBMQx2, IBMQ London and IBMQ-Rome) of IBM, as well as in different simulators (Pennylane, Qiskit-Aer and Cirq). By using a small number of data sets such as 126 COVID-19 and 100 Normal CT images, we obtained a positive or negative classification of COVID-19 with 90% success in classical computers, while we achieved a high success rate of 94-100% in quantum computers. Also, according to the results obtained, machine learning process in classical computers requiring more processors and time than quantum computers can be realized in a very short time with a very small quantum processor such as 4 qubits in quantum computers. If the size of the data set is small; Due to the superior properties of quantum, it is seen that according to the classification of COVID-19 and Normal, in terms of machine learning, quantum computers seem to outperform traditional computers.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.07.20227306v1" target="_blank">COVID-19 detection on IBM quantum computer with classical-quantum transfer learning</a>
</div></li>
<li><strong>Synthetic Reproduction and Augmentation of COVID-19 Case Reporting Data by Agent-Based Simulation</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
We generate synthetic data documenting COVID-19 cases in Austria by the means of an agent-based simulation model. The model simulates the transmission of the SARS-CoV-2 virus in a statistical replica of the population and reproduces typical patient pathways on an individual basis while simultaneously integrating historical data on the implementation and expiration of population-wide countermeasures. The resulting data semantically and statistically aligns with an official epidemiological case reporting data set and provides an easily accessible, consistent and augmented alternative. Our synthetic data set provides additional insight into the spread of the epidemic by synthesizing information that cannot be recorded in reality.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.07.20227462v1" target="_blank">Synthetic Reproduction and Augmentation of COVID-19 Case Reporting Data by Agent-Based Simulation</a>
</div></li>
</ul>
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: FSD201;   Drug: Placebo<br/><b>Sponsor</b>:   FSD Pharma, Inc.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy of Probiotics in Reducing Symptoms of COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Dietary Supplement: Probiotics (2 strains 10x10^9 UFC);   Dietary Supplement: Placebo (potato starch and magnesium stearate)<br/><b>Sponsors</b>:   Centre de recherche du Centre hospitalier universitaire de Sherbrooke;   Lallemand Health Solutions<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: COVI-VAC;   Other: Placebo<br/><b>Sponsor</b>:   Codagenix, Inc<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study of Niclosamide in Moderate Hospitalized Coronavirus-19 (COVID-19) Patients</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: Niclosamide;   Drug: Placebo<br/><b>Sponsor</b>:   ANA Therapeutics<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: 0.5% Povidone Iodine;   Drug: 0.12% Chlorhexidine Gluconate Mouth Rinse;   Drug: 1% Hydrogen Peroxide;   Drug: 0.9% Normal Saline<br/><b>Sponsor</b>:   Ohio State University<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: BI 764198;   Drug: Placebo<br/><b>Sponsor</b>:   Boehringer Ingelheim<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Comparison of Two Different Doses of Bemiparin in COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Drug: Bemiparin sodium<br/><b>Sponsor</b>:   Clinica Universidad de Navarra, Universidad de Navarra<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>An Outpatient Study Investigating Non-prescription Treatments for COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Other: chlorine dioxide;   Dietary Supplement: zinc acetate;   Drug: Famotidine;   Other: placebo;   Dietary Supplement: lactoferrin, green tea extract<br/><b>Sponsor</b>:   Profact, Inc.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Drug: Nafamostat Mesilate<br/><b>Sponsor</b>:   Chong Kun Dang Pharmaceutical<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Angiotensin 1-7 as a Therapy in the Treatment of COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Drug: Angiotensin 1-7<br/><b>Sponsors</b>:   Rambam Health Care Campus;   Constant Therapeutics<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Hyperimmune Plasma for Patients With COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Other: treated with hyperimmune plasma<br/><b>Sponsor</b>:   ANNA FALANGA<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Intravenous Infusion of CAP-1002 in Patients With COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Biological: CAP-1002;   Biological: Placebo<br/><b>Sponsor</b>:   Capricor Inc.<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Clarithromycin 500mg;   Drug: Azithromycin;   Drug: Placebo<br/><b>Sponsor</b>:   South Valley University<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: CNM-ZnAg;   Drug: Placebo<br/><b>Sponsors</b>:   Clene Nanomedicine;   ICL Pharma;   Azidus Brazil<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 in COVID-19 Patients</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Biological: Administration of Equine immunoglobulin anti SARS-CoV-2<br/><b>Sponsors</b>:   Caja Costarricense de Seguro Social;   Universidad de Costa Rica;   Ministry of Health Costa Rica<br/><b>Recruiting</b></p></li>
</ul>
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Pilot study for the evaluation of safety profile of a potential inhibitor of SARS-CoV-2 endocytosis</strong> - CONCLUSIONS: We demonstrated that Endovir Stop spray is safe. The next step would be the administration of the efficacy of the spray by testing it to a wider range of people and see whether there is a reduced infection rate of SARS-CoV-2 in the treated subjects than in the non-treated individuals.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Natural compounds as inhibitors of SARS-CoV-2 endocytosis: A promising approach against COVID-19</strong> - CONCLUSIONS: We reviewed natural compounds with potential antiviral activity against SARS-CoV-2 that could be used as a treatment for COVID-19.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets</strong> - CONCLUSIONS: This study, for the first time, revealed the niacin-associated molecular functions and pharmacological targets for treating CRC/COVID-19, as COVID-19 remains a serious pandemic. But the findings were not validated in actual CRC patients infected with COVID-19, so further investigation is needed to confirm the potential use of niacin for treating CRC/COVID-19.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Optimization and Evaluation of Propolis liposomes as a promising therapeutic approach for COVID-19</strong> - The present work aimed to develop an optimized liposomal formulation for enhancing the anti-viral activity of propolis against COVID-19. Docking studies were performed for certain components of Egyptian Propolis using Avigan, Hydroxychloroquine and Remdesivir as standard antivirals against both COVID-19 3CL-protease and S1 spike protein. Response surface methodology and modified injection method were implemented to maximize the entrapment efficiency and release of the liposomal formulation. The…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers</strong> - CONCLUSIONS: The data indicate that PPMO have the ability to potently and specifically suppress SARS-CoV-2 growth and are promising candidates for further preclinical development.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells</strong> - The acid sphingomyelinase/ceramide system plays an important role in bacterial and viral infections. Here we report that either pharmacological inhibition of acid sphingomyelinase with amitriptyline, imipramine, fluoxetine, sertraline, escitalopram, or maprotiline, or genetic downregulation of the enzyme prevents infection of cultured cells or freshy isolated human nasal epithelial cells with SARS-CoV-2 or pseudoviral pp-VSV-SARS-CoV-2 particles expressing spike, a bona fide system mimicking…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Nanoconjugates-Based Stem Cell Therapy for the Management of COVID-19</strong> - A potential ability of stem cells (SCs) is to regenerate and repair tissues in the human body by providing great prospects for therapeutic applications in the field of medicine. Currently, SC therapy is used in various conditions like diabetes, neurodegenerative disorders, etc. but faces some limitations like patient biocompatibility and chances of cross-infection. SCs are further modulated with nanoconjugates to overcome such challenges and will offer an advantage in the treatment of COVID-19….</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19: Is there a role for immunonutrition in obese patient?</strong> - On December 12, 2019 a new coronavirus (SARS-CoV-2) emerged in Wuhan, China, triggering a pandemic of severe acute respiratory syndrome in humans (COVID-19). Today, the scientific community is investing all the resources available to find any therapy and prevention strategies to defeat COVID-19. In this context, immunonutrition can play a pivotal role in improving immune responses against viral infections. Immunonutrition has been based on the concept that malnutrition impairs immune function….</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients</strong> - Coronavirus disease 2019 (COVID-19) pandemic has affected health care systems worldwide. Severe presentations of COVID-19 such as severe pneumonia and acute respiratory distress syndrome (ARDS) have been associated with the post-viral activation and release of cytokine/chemokines which leads to a “cytokine storm” causing inflammatory response and destruction, mainly affecting the lungs. COVID-19 activation of transcription factor, NF-kappa B (NF-κB) in various cells such as macrophages of lung,…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection</strong> - To circumvent the devastating pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a humanized decoy antibody (ACE2-Fc fusion protein) was designed to target the interaction between viral spike protein and its cellular receptor, angiotensin-converting enzyme 2 (ACE2). First, we demonstrated that ACE2-Fc could specifically abrogate virus replication by blocking the entry of SARS-CoV-2 spike-expressing pseudotyped virus into both ACE2-expressing lung cells and…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A pharmacology-based comprehensive review on medicinal plants and phytoactive constituents possibly effective in the management of COVID-19</strong> - Arisen in China, COVID-19 (SARS-CoV-II) is a novel coronavirus that has been expanding fast worldwide. Till now, no definite remedial drug or vaccine has been identified for COVID-19 treatment. Still, for a majority of infected patients, supportive therapy is the cornerstone of the management plan. To the importance of managing the COVID-19 pandemic, this article proposed to collecting capable medicinal plants and bioactive components in both treat and supportive therapy of this novel viral…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M(pro) and cathepsin L</strong> - The main protease (M^(pro)) of SARS-CoV-2 is a key antiviral drug target. While most M^(pro) inhibitors have a γ-lactam glutamine surrogate at the P1 position, we recently discovered several M^(pro) inhibitors have hydrophobic moieties at the P1 site, including calpain inhibitors II and XII, which are also active against human cathepsin L, a host-protease that is important for viral entry. In this study, we solved X-ray crystal structures of M^(pro) in complex with calpain inhibitors II and XII,…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2</strong> - Binding to the host receptor is a critical initial step for the coronavirus SARS-CoV-2 spike protein to enter into target cells and trigger virus transmission. A detailed dynamic and energetic view of the binding mechanisms underlying virus entry is not fully understood and the consensus around the molecular origins behind binding preferences of SARS-CoV-2 for binding with the angiotensin-converting enzyme 2 (ACE2) host receptor is yet to be established. In this work, we performed a…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Does eNOS derived nitric oxide protect the young from severe COVID-19 complications?</strong> - The COVID-19 pandemic poses an imminent threat to humanity, especially to the elderly. The molecular mechanisms underpinning the age-dependent disparity for disease progression is not clear. COVID-19 is both a respiratory and a vascular disease in severe patients. The damage endothelial system provides a good explanation for the various complications seen in COVID-19 patients. These observations lead us to suspect that endothelial cells are a barrier that must be breached before progression to…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial “BromhexIne and Spironolactone for CoronvirUs Infection requiring hospiTalization (BISCUIT)”</strong> - The article focuses on effective treatment of the novel coronavirus infection (COVID-19) at early stages and substantiates the requirement for antiviral therapy and for decreasing the viral load to prevent the infection progression. The absence of a specific antiviral therapy for the SARS-CoV-2 virus is stated. The authors analyzed results of early randomized studies using lopinavir/ritonavir, remdesivir, and favipiravir in COVID-19 and their potential for the treatment of novel coronavirus…</p></li>
</ul>
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SARS-CoV-2 예방을 위한 mRNA기반 항원보강제 혼합물 합성 방법</strong> - 본 발명은 SARS-CoV-2(코로나 바이러스) 예방을 위한 mRNA 항원보강제에 관한 것으로 코로나 바이러스에 대한 백신으로서 상기의 항원에 대한 예방을 목적으로 하고 있다. 아이디어에는 보강제에 해당하는 완전프로인트항원보강제(CFA)와 불완전프로인트항원보강제(IFA), 번역과 안정성의 최적화가 된 mRNA, mRNA 운반체, 양이온성 지질 나노입자(lipid nanoparticles)로 구성되며 기존의 백신에 비해 효율성과 안정성의 측면에서 더 향상된 효과를 가지고 있다.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Methods for treating Arenaviridae and Coronaviridae virus infections</strong> - Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I:</p></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">wherein the ’ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.</p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Atemschutz-Baukastensystem</strong> -
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Atemschutz-Baukastensystem, das aufweist:</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">eine auf zumindest Mund und Nase einer Person aufsetzbare Maske (1), die einen Eingang (11) und einen Ausgang (12) aufweist, und</li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">mindestens einen Schlauch (3, 31, 32),</li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">wobei sämtliche Komponenten des Atemschutz-Baukastensystems modular ausgebildet und über Steckverbindungen oder Schraubverbindungen (115, 125, 155, 165, 175, 215, 315, 75, 915) miteinander verbindbar sind, um der Maske (1) Luft über deren Eingang (11) zuzuführen und/oder ausgeatmete Luft vom Ausgang (12) der Maske (1) wegzuführen.</li>
</ul>
<img alt="embedded image" id="EMI-D00000"/>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vorrichtung zur Übergabe und Dekontamination von mit Krankheitserregern kontaminierten Gegenständen oder Erzeugnissen</strong> -
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Vorrichtung zur Übergabe von mit Krankheitserregern kontaminierten Gegenständen oder Erzeugnissen nach einer Dekontamination, umfassend eine Einrichtung zur Dekontamination der mit Krankheitserregern kontaminierten Gegenstände oder Erzeugnisse mit mindestens einer UV-Strahlungsquelle (24), eine Durchzugseinrichtung mit Ein- und/oder Ausgabebereichen für die kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse, dadurch gekennzeichnet, dass die Durchzugseinrichtung im Eingang bzw. im Ausgang zum Ein- und/oder Ausgabebereich angeordnete sich paarweise gegenüberliegende Walzen (17) und Räder (4) umfasst, die zum Einzug bzw. zur Ausgabe der kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse vorgesehen sind, wobei die Walzen (17) und die Räder (4) durch im Ein- und/oder Ausgabebereich angeordnete Sensoren (23) und einer elektronische Kontrolleinheit (27) in Bewegung bringbar sind, wobei die Gegenstände oder Erzeugnisse in den Bereich der Einrichtung zur Dekontamination förderbar sind, der zwischen den paarweise angeordneten Walzen (17) und Rädern (4) vorgesehen ist, welcher sich gegenüberliegende Platten (25) aus Quarzglas oder einem UV-transparenten Polymermaterial, wie Graphen oder Kunstglas umfasst, über bzw. unter welchen die UV-Strahlungsquelle (24) angeordnet ist, welche als UVC-LED-Leiste und/oder Modul mit mindestens einer LED-Lampe ausgebildet ist.</p></li>
</ul>
<img alt="embedded image" id="EMI-D00000"/>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물</strong> - 본 발명은 화학식 1로 표시되는 화합물, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환 예방 또는 치료용 약학적 조성물을 제공한다. [화학식 1] .</p>
<pre><code> JPEG
112020094463686-pat00017.jpg
48
135</code></pre></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>新型冠状病毒中和性抗体滴度检测ELISA试剂盒</strong> - 本发明提供一种新型冠状病毒中和性抗体滴度检测ELISA试剂盒，其中包括：包被有生物素‑链霉亲和素标记的人ACE2蛋白的酶标板、辣根过氧化酶标记的新型冠状病毒RBD蛋白、新型冠状病毒中和性抗体阳性对照、包被液、洗涤液、稀释液、封闭液、显色液和终止液等。该试剂盒具有成本低，操作简单，高灵敏度、高特异性、高准确度的特点，可用于新型冠状病毒中和抗体的批量、快速检测。</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Zahnbürstenaufsatz, elektrische Versorgungseinheit einer elektrischen Zahnbürste, elektrische Zahnbürste mit einem Zahnbürstenaufsatz, Zahnbürste sowie Testaufsatz für eine elektrische Zahnbürste</strong> -</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Zahnbürstenaufsatz für eine elektrische Zahnbürste (20) umfassend einen Koppelabschnitt (2), über den der Zahnbürstenaufsatz (1) mit einer elektrischen Versorgungseinheit (10) der elektrischen Zahnbürste (20) verbindbar ist und einen Bürstenabschnitt (3), der zur Reinigung der Zähne ausgebildete Reinigungsmittel (3.1) aufweist, dadurch gekennzeichnet, dass an dem Zahnbürstenaufsatz (1) eine Sensoreinheit (4) vorgesehen ist, die dazu ausgebildet ist, selektiv das Vorhandensein eines Virus oder eines Antigen im Speichel eines Nutzers des Zahnbürstenaufsatzes (1) durch Messen zumindest eines virusspezifischen Parameters zu bestimmen.</p></li>
</ul>
<img alt="embedded image" id="EMI-D00000"/>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Wasserpfeife mit Hygienefunktion</strong> -
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Hygiene-Mundstückelement (100), aufweisend einen ersten Endabschnitt (103), welcher ausgebildet ist zur Verbindung mit einem Griff-Mundstückelement (200) einer Wasserpfeife (400) und aufweisend einen zweiten Endabschnitt (104), welcher als mundseitiges, freies Ende ausgebildet ist, wobei das Hygiene-Mundstückelement (100) ein erstes Filterelement (101) aufweist, wobei das erste Filterelement (101) wenigstens ein adsorbierendes Material umfasst und/oder wobei das Hygiene-Mundstückelement (100) ein zweites Filterelement (102) aufweist, wobei das zweite Filterelement (102) Metalloxid und/oder elektrostatisch geladene Fasern umfasst.</p></li>
</ul>
<img alt="embedded image" id="EMI-D00000"/>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>알츠하이머병 혹은 뇌졸중의 뉴로인플라마섬의 치료제로서 디디에스 혹은 그 유도체</strong> - 목표 / 배경 :이 연구는 신경-정신과 증상을 측면과 구별하기 위해 2018 ‘NIA-AA 연구 프레임 워크’에 따라 뉴로인플라마섬 경쟁자로서 4, 4’- 디아미노디 페닐설폰(DDS, 디디에스)으로 치료받은 알츠하이머병(AD) 환자를 조사했습니다. 방법 : 서울 연구에서는 AD 진단 기준에 따라 2005 년 1 월부터 2020 년 6 월까지 보관된 소록도 국립병원 EDI 데이터베이스의 AD와 항AD약물(AAD)의 효과를 분석하여 ICD-9와 10 개의 코드를 이용하여 검색 하였습니다. 새로운 바이오마커 (D)를 사용하여 AAD로 인한 AD 증상과 신경정신병적 증상을 관리하여 수치 임상 병기를 분류했습니다. 우리는 서울 연구에서 뉴로인플라마섬 경쟁자로서 뇌경색 및 DDS 관련 사례를 보고합니다. 결과 : DDS는 DDS를 처방했거나 처방하지 않은 사람들과 AD의 비율을 비교할 때 뉴로인플라마섬 경쟁자였습니다. (D)를 도입함으로써, AD의 진행은 NCS 병기 결정을 통해 모니터링 하였습니다. AAD 또는 신경병리 증상을 구별하고 DDS로 치료했습니다. AD는 AAD에 의해 악화될 수 있고 DDS에 의해 경미한 인지 장애로 회복될 수 있습니다. 우리는 서울 연구에서 뇌경색이 발생하기 전과 후에 뉴로인플라마섬 경쟁자로서 DDS가 어떤 역할을 하는지를 임상적으로 확인했습니다. 결론 : DDS는 RBS 분할에 의한 정규/비정규적 우비퀴틴화, NLRP3 inflammasome 형성, Higgins의 캐스케이드 및 철이 풍부한 강자성 나노 입자를 차단하는 역할을 합니다. 바이오마커 (D)를 통하여 DDS로 AD를 예방하고 치료할 수 있습니다. AD에 대한 예방 및 치료 방법으로 뉴로인플라마섬을 치료하는 것을 수치 임상 병기(NCS, Numeric clinical staging)를 통하여 증명하고 있습니다.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A electronic biometric system</strong> - An electronic biometric system, the system comprising:</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">a biometric detection means arranged to:</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">detect at least one biological characteristic of a person</p></li>
</ul>
<script>AOS.init();</script></body></html>

166
archive-daily-dose/11 November, 2020.html Normal file
View File

@ -0,0 +1,166 @@
<!DOCTYPE html>
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
<meta charset="utf-8"/>
<meta content="pandoc" name="generator"/>
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
<title>11 November, 2020</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
.display.math{display: block; text-align: center; margin: 0.5rem auto;}
</style>
<!--[if lt IE 9]>
<script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
<![endif]-->
<title>Daily-Dose</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="daily-dose">Daily-Dose</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-apple-subreddit">From Apple Subreddit</a></li>
<li><a href="#from-hacker-news">From Hacker News</a></li>
<li><a href="#from-new-yorker">From New Yorker</a></li>
<li><a href="#from-the-hindu-sports">From The Hindu: Sports</a></li>
<li><a href="#from-the-hindu-national-news">From The Hindu: National News</a></li>
<li><a href="#from-bbc-europe">From BBC: Europe</a></li>
<li><a href="#from-ars-technica">From Ars Technica</a></li>
<li><a href="#from-jokes-subreddit">From Jokes Subreddit</a></li>
</ul>
<h1 data-aos="fade-right" id="from-apple-subreddit">From Apple Subreddit</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Apple’s “One More Thing” | Post-Event Megathread</strong></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Apple unveils M1, its first system-on-a-chip for portable Mac computers</strong></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Apple will release macOS Big Sur on November 12th</strong></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Apple Store is down ahead of ‘One More Thing Mac’ event</strong></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>New MacBook Air Announced as First Apple Silicon Mac With M1 Chip</strong></li>
</ul>
<h1 data-aos="fade-right" id="from-hacker-news">From Hacker News</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Apple unveils M1, its first system-on-a-chip for portable Mac computers</strong> - <a href="https://news.ycombinator.com/item?id=25049079">Comments</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>How to get root on Ubuntu 20.04 by pretending nobody’s /home</strong> - <a href="https://news.ycombinator.com/item?id=25053238">Comments</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>On Apple’s Piss-Poor Documentation</strong> - <a href="https://news.ycombinator.com/item?id=25046691">Comments</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Introducing the next generation of Mac</strong> - <a href="https://news.ycombinator.com/item?id=25049528">Comments</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>.NET 5.0</strong> - <a href="https://news.ycombinator.com/item?id=25047409">Comments</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>YubiKey Biometric Security Key</strong> - <a href="https://news.ycombinator.com/item?id=25053644">Comments</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Lonely Work of Moderating Hacker News (2019)</strong> - <a href="https://news.ycombinator.com/item?id=25048415">Comments</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>InfluxDB 2.0 Is Out</strong> - <a href="https://news.ycombinator.com/item?id=25053812">Comments</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Origins of the youtube-dl project</strong> - <a href="https://news.ycombinator.com/item?id=25047818">Comments</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Using Rust to Scale Elixir for 11M Concurrent Users</strong> - <a href="https://news.ycombinator.com/item?id=25053553">Comments</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-new-yorker">From New Yorker</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Voting Trump Out Is Not Enough</strong> - The need in this country dwarfs the best of what Joe Biden has put on the table for changing our current condition.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Kamala Harris Makes History</strong> - Biden’s selection of Harris is tantamount to an anointment: she is going to be the Democratic Party.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Outside the White House, the Site of Anti-Trump Protests Hosts a Celebration</strong> - Five months ago, protesters in Lafayette Square were tear-gassed to make way for a Presidential photo op. On Saturday, after Joe Biden’s victory was announced, the streets around the square were the scene of a party.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Supreme Court Justice Brett Kavanaugh’s Vote May Save Obamacare This Time</strong> - In oral arguments on Tuesday, Kavanaugh appeared inclined to let the Affordable Care Act stand even if the individual mandate is struck down.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>As Trump Gained Latino Support in Florida, Biden’s Campaign Ignored Warnings</strong> - Members of the Democrat’s community-outreach team say that the effort was underfunded, unfocussed, and ineffective.</p></li>
</ul>
<h1 data-aos="fade-right" id="from-the-hindu-sports">From The Hindu: Sports</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Full auction for IPL 2021</strong> - It is understood that BCCI has plans to add a ninth team to the fold</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Morikawa not intimidated by Masters challenge</strong> - PGA Championship winner says he has done his prep work</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Lovlina fighting to remain focused</strong> - Stays afloat in the face of a string of adversities</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Six-time champion Marquez not to return before 2021</strong> - He has been sidelined since crashing out of the Spanish Grand Prix on July 19</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Prannoy working on improving his fitness</strong> - The shuttler aims to qualify for the Olympic Games and better his ranking</p></li>
</ul>
<h1 data-aos="fade-right" id="from-the-hindu-national-news">From The Hindu: National News</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>India gifts 20 horses, 10 mine detection dogs to Bangladesh Army</strong> - India on Tuesday gifted 20 fully trained military horses and 10 mine detection dogs to the Bangladesh Army. These were trained by the Remount and Vete</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Punjab recruits 482 new medical officers amid COVID-19 pandemic</strong> - Move to meet staff shortages, provide employment</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Bihar Assembly polls | NDA overcomes stiff challenge to retain power in Bihar</strong> - The ruling coalition won 125 seats in the 243-member State Assembly against 110 clinched by the Opposition Grand Alliance.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Legacy war in Nandigram as Trinamool, its Minister hold separate rallies</strong> - In a veiled attack on party, Suvendu Adhikari says they will meet “on the battlefield”</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>CBI books Best Foods, others in bank fraud</strong> - Bank consortium cheated of ₹1,006.46 crore</p></li>
</ul>
<h1 data-aos="fade-right" id="from-bbc-europe">From BBC: Europe</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Nagorno-Karabakh: Russia deploys peacekeeping troops to region</strong> - Hundreds of troops are deployed after Armenia and Azerbaijan agreed to end six weeks of war.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Denmark mink cull: Government admits culling had no legal basis</strong> - PM Mette Frederiksen apologises for going ahead with the mass cull of mink without new legislation.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Catholic Church abuse: Vatican defends handling of McCarrick case</strong> - Theodore McCarrick was expelled from the priesthood after an inquiry found him guilty of sex abuse.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Coronavirus: Russia resists lockdown and pins hopes on vaccine</strong> - An ice rink is being used to treat Covid patients as Russia hopes its Sputnik V vaccine will resolve the crisis.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Coronavirus: Turkish Germans raise new Covid vaccine hopes</strong> - A husband and wife from Turkish immigrant families spearhead a vaccine breakthrough.</p></li>
</ul>
<h1 data-aos="fade-right" id="from-ars-technica">From Ars Technica</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>England faces a proper “argy-bargy” in Pennyworth S2 trailer</strong> - S1 now available for streaming on Amazon Prime, so it’s the perfect time to catch up. - <a href="https://arstechnica.com/?p=1722348">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Dutch scientists reconstruct spread of coronavirus through mink farms</strong> - So far, however, no evidence of dangerous mutations being selected in mink. - <a href="https://arstechnica.com/?p=1722350">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ubuntu fixes bugs that standard users could use to become root</strong> - A handful of commands was all it took for untrusted users to become all-powerful. - <a href="https://arstechnica.com/?p=1722318">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>James Corden is a snarky AI that might take out humanity in Superintelligence</strong> - Director Ben Falcone opted to release the film on HBO Max even before the pandemic. - <a href="https://arstechnica.com/?p=1722240">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Microsoft engineer gets nine years for stealing $10M from Microsoft</strong> - The defendant tried—and failed—to use bitcoin to cover his tracks. - <a href="https://arstechnica.com/?p=1721845">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-jokes-subreddit">From Jokes Subreddit</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>How do you lure a pervert? (NSFW)</strong> - <!-- SC_OFF --></p>
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Just add the NSFW tag.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/GodDarnBatman"> /u/GodDarnBatman </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/jrupa3/how_do_you_lure_a_pervert_nsfw/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/jrupa3/how_do_you_lure_a_pervert_nsfw/">[comments]</a></span></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>“Okay Fred, Shaggy and Daphne, can you name an animal that lives in Africa and has a large horn on its face?” “Rhino!”</strong> - <!-- SC_OFF --></p>
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“We know you know the answer, Scooby, but it’s not your turn!”
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/honolulu_oahu_mod"> /u/honolulu_oahu_mod </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/jrjl9g/okay_fred_shaggy_and_daphne_can_you_name_an/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/jrjl9g/okay_fred_shaggy_and_daphne_can_you_name_an/">[comments]</a></span></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Jewish pilot and Chinese pilot are flying together for the 1st time.</strong> - <!-- SC_OFF --></p>
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
An hour into the flight, the Jewish pilot says to his Chinese counterpart “I don’t like the Chinese.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Stunned, the Chinese pilot replies “Why don’t you like the Chinese?”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“Well” says the Jew, “the Chinese bombed Pearl Harbor.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Even more stunned, he replies ”The Chinese didn’t bomb Pearl Harbor! It was the Japanese!”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“Well, Chinese, Japanese, Vietnamese, they’re all the same to me.” says the Jew.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The Chinese pilot is seething at this, and after a while he turns to his Jewish counterpart to say “I don’t like the Jews.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“What?” asks the Jew. “Why don’t you like Jews?”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“Well” he says, “The Jews sank the Titanic.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The Jewish pilot scoffs at this, “The Jews didn’t sink the Titanic! An Iceberg sank the Titanic!”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“Well” he replies, “Iceberg, Goldberg, Rosenberg, they’re all the same to me.”
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/-ChipButty-"> /u/-ChipButty- </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/jrdmu9/a_jewish_pilot_and_chinese_pilot_are_flying/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/jrdmu9/a_jewish_pilot_and_chinese_pilot_are_flying/">[comments]</a></span></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Why do vampires usually pull out during sex?</strong> - <!-- SC_OFF --></p>
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
They can’t come inside without an invitation.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/RoosterShield"> /u/RoosterShield </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/jro29r/why_do_vampires_usually_pull_out_during_sex/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/jro29r/why_do_vampires_usually_pull_out_during_sex/">[comments]</a></span></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>What should we do with people who rely on government handouts, but refuse to work?</strong> - <!-- SC_OFF --></p>
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Kick them out of Congress
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/VERBERD"> /u/VERBERD </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/jrwhb6/what_should_we_do_with_people_who_rely_on/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/jrwhb6/what_should_we_do_with_people_who_rely_on/">[comments]</a></span></p></li>
</ul>
<script>AOS.init();</script></body></html>

8
index.html
View File

@ -13,9 +13,9 @@ Archive | Daily Reports
<li> <a href="#covid-19">Covid-19</a>
</li></li></ul>
<h2 id="daily-dose">Daily Dose</h2>
<ul id="daily-dose-list"><li><a href="./archive-daily-dose/10 November, 2020.html">10 November, 2020</a></li>
<ul id="daily-dose-list"><li><a href="./archive-daily-dose/11 November, 2020.html">11 November, 2020</a></li>
</ul>
<h2 id="covid-19">Covid-19
<ul id="covid-19-list">
<h2 id="covid-19">Covid-19</h2>
<ul id="covid-19-list"><li><a href="./archive-covid-19/11 November, 2020.html">11 November, 2020</a></li>
</ul>
</h2></body></html>
</body></html>